• News
  • SAN DIEGO
  • BioTech

FDA gives Isis green light for cholesterol drug

The U.S. Food and Drug Administration has approved a new cholesterol treatment from Carlsbad’s Isis Pharmaceuticals (Nasdaq: ISIS) and its French partner Genzyme, clearing the path for Isis' first drug to reach market.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
50.94
  -0.68  
- 1.32%
1,530,635,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
11/03/2014 O Neil, Patrick R 1,500 Sell $69,255
11/03/2014 O Neil, Patrick R 1,500 Sell $69,255
11/03/2014 O Neil, Patrick R 1,500 Exchange $10,875
10/30/2014 Parshall, B Lynne 11,071 Sell $499,535
10/30/2014 Parshall, B Lynne 11,071 Exchange $98,939

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!